LITTLETON, Mass., May 14 /PRNewswire/ -- Still River Systems, Inc. announces successful clinical beam extraction from the first production unit of the world's smallest high-energy proton therapy accelerator. Powerful proton beams are used for the precise treatment of cancer by delivering a highly focused beam of radiation to the tumor while reducing the damage to surrounding healthy tissue and vital organs. This unique accelerator, the world's first superconducting synchrocyclotron, has been specially designed for the Monarch250 Proton Therapy System currently being installed at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO, a National Cancer Institute (NCI) Comprehensive Cancer Center.
Accelerators have been used in proton therapy for 60 years, but their size, complexity, and cost have limited adoption of this cancer therapy to a few centers around the world. Still River Systems, based on technology developed at the Massachusetts Institute of Technology's Plasma Science Fusion Center, has now harnessed breakthroughs in superconducting technology to create the world's smallest high-energy proton therapy accelerator. "The successful testing of our first production accelerator is the culmination of several years of development", explains Dr. Kenneth Gall, Founder and Chief Technology Officer. "We have used advanced superconducting technology and a unique synchrocyclotron design to build a modern accelerator optimized for proton therapy." With a diameter of only 6 feet and a weight of 20 tons, this accelerator generates a powerful 250 MeV proton beam.
The Siteman Cancer Center will be the first in the world to receiv